Company intelligence / Profile preview

Quantovir

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Quantovir is a biotechnology company focused on the discovery and development of novel antiviral small molecules. The company was established to advance research into potent inhibitors of the SARS-CoV-2 main protease (Mpro), a critical enzyme for viral replication. By targeting conserved regions of the virus, Quantovir aims to develop oral therapeutics that remain effective against emerging variants. The company's work is rooted in structural biology and medicinal chemistry expertise derived from leading academic research at Columbia University.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Columbia University

Beyond the preview

Go deeper on Quantovir.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quantovir.

Explore the full profile